T
About
Tacalyx GmbH develops novel anticancer therapeutics targeting tumor-associated carbohydrate antigens (TACAs). It is based in Berlin, Germany, and was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces in Potsdam.
Services
Antibody generation
Generates antibodies for its TACA-targeting programs.
Cell-based assays
Runs cell-based assays to support antibody drug development and pipeline work.
Glycobiology
Performs glycobiology work focused on tumor-associated carbohydrate antigens.
Antibody and protein biochemistry
Carries out antibody and protein biochemistry for therapeutic development.
Capabilities
- Assays and studies
- Antibodies
- Cell-based assays
- ADCs
- Therapeutic areas
- Cancer
Modalities and species
- Modalities
- Antibody
- ADC
Industries served
- Biotech
Details
- Founded
- 2019
- Based in
- Berlin, Germany
- Sites
- Potsdam, Germany
- General enquiry
- info@tacalyx.com on their site
- Phone
- +49 30 407 237 10